Clover Flex Sihuan Pharmaceutical's exclusive agent for botulinum toxin Letibao is approved for marketing by NMPA Vertex's Kalydeco for cystic fibrosis is close to approval in the EU Two imported new ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global leader in cystic fibrosis (CF) treatments. CF is a genetic ...

Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

The 5K run and walk raises money for the Cystic Fibrosis Association of North Dakota. There were 1,874 people who registered for Thursday's 35th annual event. Jakson Ensign and Dawson Balzer ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P. Morgan Healthcare ...

Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.